title: [Bone mineral density in female patients with systemic lupus erythematosus treated with high glucocorticoid doses].
abstract: OBJECTIVE
  To study the bone mineral density (BMD) in premenopausal women with systemic lupus erythematosus receiving glucocorticoids (GL) and at 6 months, when the dose of GL was decreased to a level below half of the initial dose.
  
  
  METHODS
  Twelve premenopausal women with SLE were prospectively studied after initiating prednisone therapy at a dose > or = 0.5 mg/kg/day. A densitometric study was performed (Hologic 1000 QDR) of the lumbar spine and femoral neck. Levels of osteocalcine (BGP), catacalcine (PDN-21), testosterone in plasma and saliva, and dehydroepiandrosterone sulphate (DHEAS) were measured. Measurements were repeated after 6 months.
  
  
  RESULTS
  The initial mean dose of prednisone was 40 +/- 10.2 mg/day (0.66 mg/kg/day) with an accumulated dose of 27.6 +/- 23 g. Lumbar and femoral BMD were 1 +/- 0.13 and 0.831 +/- 0.07 g/cm2, respectively. A significant increase was observed in BGP an adrogen levels studied after a 6 months when the dose of GL was decreased to a mean dose of 13.9 +/- 7.5 mg/day (0.23 mg/kg/day), whereas no differences were found in BMD values. In none of the two phases of the study were osteoporosis, correlations between BMD and BGP, between PDN-21 and androgens or with the accumulated or punctual doses of GL documented.
  
  
  CONCLUSIONS
  No decrease in BMD was observed after 6 months of therapy with high doses of GL. In contrast, an increase in BGP and androgenic status was observed when the GL dose was decreased.
authors.affiliation: Servicio de Medicina Interna, Hospital de Bellvitge-Princeps d'Espanya, CSU de Bellvitge, L'Hospitalet de Llobregat, Barcelona.
authors.forename: F
authors.initials: F
authors.lastname: Formiga
authors.forename: I
authors.initials: I
authors.lastname: Moga
authors.forename: M A
authors.initials: MA
authors.lastname: Navarro
authors.forename: J M
authors.initials: JM
authors.lastname: Nolla
authors.forename: R
authors.initials: R
authors.lastname: Bonnin
authors.forename: D
authors.initials: D
authors.lastname: Roig-Escofet
authors.forename: R
authors.initials: R
authors.lastname: Pujol
mesh_terms: D000328:Adult; D015519:Bone Density / Q000187:drug effects*; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000378:metabolism; D011241:Prednisone / Q000008:administration & dosage*; D017697:Premenopause; D011446:Prospective Studies
chemical_list: D005938:Glucocorticoids; D011241:Prednisone